Sanofi
Q2 2025 13F-HR Holdings
Net value change ($000)
—
New positions
10
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MGTX | 79,529 | — |
| NVAX | 43,347 | — |
| ANAB | 18,247 | — |
| INBX | 16,524 | — |
| OMDA | 9,606 | — |
| LAVA Therapeutics NV | 2,534 | — |
| ELDN | 2,209 | — |
| INOZYME PHARMA INC | 1,773 | — |
| IGM Biosciences, Inc. | 1,612 | — |
| QTTB | 364 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|